Merck's Dr Dave Maraldo outlines 3 principles for placing manufacturing capacity and how end-to-end ADC supply chains could shift platform thinking.
|Articles|December 1, 2016
- BioPharm International-12-01-2016
- Volume 29
- Issue 12
Automated Microscope for Multimodal Imaging
Zeiss’s Axio Observer inverted microscope platform includes new automation features, allowing researchers to perform multimodal imaging of living and fixed specimens.
Advertisement
Zeiss’s Axio Observer inverted microscope platform includes new automation features, allowing researchers to perform multimodal imaging of living and fixed specimens. Among these features is Autocorr, a technology that allows adaption of immersion objectives to varying sample carriers and imaging conditions. The correction of spherical aberrations results in improved image contrast, higher resolution, and more efficient fluorescence detection.
The microscope includes a new autoimmersion option that builds up and maintains stable water immersion without evaporation or air bubbles, and is compatible with multiple water immersion objectives in the nosepiece. The Axio Observer includes interfaces for imaging technologies, ranging from widefield transmitted light to 3D sectioning, fast and sensitive confocal super-resolution imaging, and structured illumination as well as photoactivated localization microscopy.
Articles in this issue
almost 10 years ago
Cross Contamination in Biopharmaalmost 10 years ago
Expression systems for the development of biosimilarsalmost 10 years ago
Large-Scale Protein Expression in Baculovirus-Infected Insect Cellsalmost 10 years ago
Chromatograph Enables Fast Recovery of Target Compoundsalmost 10 years ago
A Coiled Flow Inversion Reactor Enables Continuous Processingalmost 10 years ago
Nurturing the Relationship Between Industry and Regulatorsalmost 10 years ago
Stimulating Biosimilar Uptake: Implications for Manufacturersalmost 10 years ago
Pharmaceutical Manufacturers Gear Up for Political Changealmost 10 years ago
Options in Employee TrainingAdvertisement
Related to this article
Donidalorsen sustained a 95% reduction in hereditary angioedema attacks over 2 years, and patients switching from other prophylaxis saw a 71% drop.
FDA has effectively paused its Commissioner’s National Priority Voucher pilot and appears to have halted new complete response letter postings, according to reports. HHS says work on the program is ongoing.
A single 240 mg dose of WVE-007 cut visceral fat while preserving lean mass for 1 year, as Activin E fell by up to 88% across INLIGHT dose groups.
A single dose of Zai Lab’s long-acting bispecific ZL-1503 produced at least 90% inhibition of an atopic dermatitis signaling biomarker through Week 12 in healthy volunteers. Its 40- to 50-day half-life supports a target of dosing every 12 weeks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
Advertisement
Advertisement
Trending on BioPharm International
1
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
2
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
3
enGene Plans Year-End BLA for Detalimogene in BCG-Unresponsive NMIBC
4
Sponsors Should Plan CMC Earlier When a First-in-Human Study Could Be Pivotal, Says Former FDA Reviewer Paz Vellanki
5